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ABSTRACT
Regulation of angiotensin II type 1 receptor (AT1R)
has a pathophysiological role in hypertension,
atherosclerosis and heart failure. We started from
an observation that the 3’-untranslated region
(3’-UTR) of AT1R mRNA suppressed AT1R transla-
tion. Using affinity purification for the separation
of 3’-UTR-binding proteins and mass spectrometry
for their identification, we describe glyceraldehyde
3-phosphate dehydrogenase (GAPDH) as an AT1R
3’-UTR-binding protein. RNA electrophoretic mobil-
ity shift analysis with purified GAPDH further
demonstrated a direct interaction with the 3’-UTR
while GAPDH immunoprecipitation confirmed this
interaction with endogenous AT1R mRNA. GAPDH-
binding site was mapped to 1–100 of 3’-UTR.
GAPDH-bound target mRNAs were identified by
expression array hybridization. Analysis of second-
ary structures shared among GAPDH targets led
to the identification of a RNA motif rich in adenines
and uracils. Silencing of GAPDH increased the
expression of both endogenous and transfected
AT1R. Similarly, a decrease in GAPDH expression
by H2O2 led to an increased level of AT1R expres-
sion. Consistent with GAPDH having a central
role in H2O2-mediated AT1R regulation, both the
deletion of GAPDH-binding site and GAPDH
overexpression attenuated the effect of H2O2 on
AT1R mRNA. Taken together, GAPDH is a transla-
tional suppressor of AT1R and mediates the effect
of H2O2 on AT1R mRNA.
INTRODUCTION
Angiotensin II is a pivotal physiological regulator of
blood pressure, salt and ﬂuid homeostasis, and cardio-
vascular structure (1). Angiotensin II has two receptors
that mediate its eﬀects. The angiotensin II type 1 receptor
(AT1R) is a G-protein-coupled receptor that confers
most of the deleterious eﬀects of angiotensin II, while
the type 2 receptor confers its protective eﬀects (2,3).
Angiotensin-II-mediated triggering of AT1R has an
important role in the pathogenesis of chronic renal
failure, heart failure, hypertension and atherosclerosis.
Moreover, numerous clinical trials have demonstrated
the beneﬁcial eﬀects of pharmacologic therapy that
reduces AT1R activity in a wide variety of cardiovascular
disorders (1).
AT1R is regulated on multiple levels including
transcription, protein synthesis, degradation and signal
transduction. Regulation of AT1R expression is a
critical mechanism that modulates the activity of renin-
angiotensin system. Cell surface expression of AT1R
is regulated by receptor internalization and this is modu-
lated by multiple proteins including arrestins and ATRAP
(4). Transcriptional regulators of AT1R gene include
glucocorticoids and interleukin 1b (5). Posttranscrip-
tional regulation of the AT1R mRNA transcript has
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of AT1R expression by insulin, statins and estrogen
(6–11). However, the molecular mechanisms of mRNA-
based regulation of AT1R expression are poorly known.
Posttranscriptional control of eukaryotic gene expres-
sion comprises several levels of regulation such as
mRNA processing, export, turnover and translation.
Each regulatory step involves various combinations of
RNA-binding proteins that form dynamic messenger ribo-
nucleoproteins. We found that transfer of AT1R 30-UTR
to a reporter gene leads to down-regulation of reporter
gene expression by two mechanisms: inhibition of transla-
tion and decrease in mRNA stability. Therefore, 30-UTR
has elements both for the regulation of translation and
mRNA turnover. In most cases of transcript selective
transcriptional regulation, translational control is dictated
by binding of a RNA-binding protein to a cis acting struc-
tural element in mRNA. AT1R 30-UTR has AU-rich
destabilization element in the distal part of the AT1R
30-UTR. The binding sites for calreticulin and AUF-1
are located in this AU-rich region (6,12). Calreticulin
binds to the highly conserved last 20 bases in the 30-end
of the rat AT1A receptor 30-UTR and mediates angio-
tensin II-induced down-regulation of rat AT1R mRNA
(6) whereas the eﬀect of AUF1 binding remains unclear,
however, in general it destabilizes mRNA (12,13). We
have found that p100 regulates AT1R mRNA stability
and translation (14). We focused our eﬀorts to elucidate
the molecular mechanisms of AT1R 30-UTR mediated
translational suppression.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
is a cellular mRNA-binding protein that suppresses the
translation of viral mRNAs and inﬂuences the stability
of some cellular mRNAs (15–17). GAPDH is a multi-
functional protein best known for its pivotal glycolytic
function (18–21) and it has been found to display a
number of independent functions unrelated to its glycoly-
tic function. These include roles in apoptosis (22), micro-
tubule organization (23) and RNA-binding (17). It is
unclear how its nonglycolytic functions are regulated but
localization changes and protein–protein interactions have
been suggested to play a role (19). GAPDH is involved
with cellular hypoxic and oxidative response and it is
down-regulated by oxidative stress (24,25).
To delineate the molecular mechanisms of AT1R
mRNA regulation, we used aﬃnity puriﬁcation and mass
spectrometry to isolate and recognize mRNA-binding
proteins. We identiﬁed GAPDH as an AT1R mRNA-
binding protein that suppresses AT1R translation and
found this suppression to be regulated by oxidative
stress. In this article we describe translational suppression
as a novel mechanism of AT1R mRNA regulation and
identify GAPDH as a mediator of this eﬀect.
MATERIALS AND METHODS
Cell culture, luciferase assay andprotein extraction
Coronary artery vascular smooth muscle cells (VSMCs)
were purchased from Lonza bioscience and cultured on
smooth muscle growth medium-2 with 5% fetal bovine
serum (FBS). HEK293 cells were grown on plastic
plates on DMEM that was supplemented with 10%
FBS, ampicillin/streptomycin and glutamine. Cells were
used for 6–10 passages before replacement with fresh
early passage stocks. Constructs were transiently trans-
fected in HEK293 cells using a standard Fugene 6 pro-
tocol (Roche Diagnostics). Silencer GAPDH and negative
control siRNA (Ambion) were transfected using
Lipofectamine 2000 reagent (Invitrogen) according to
manufacturer’s instructions. VSMC were transfected
as described (26). Cells were harvested 24–72h after trans-
fection and ﬁreﬂy luciferase activities were measured
using the Dual Luciferase Assay System (Promega). The
luciferase activity was normalized to the activity of the
cotransfected renilla luciferase plasmid or total protein
content. Protein lysates were prepared using NE-PER
kit (Pierce) and the lysates were prepared according
to manufacturer’s recommendations. Protein concentra-
tions were determined by Bradford assay (Bio-Rad).
H2O2 treatment was performed as described (24).
Constructs
The constructs used have been described previously (14).
Randommutagenesis
Genemorph II EZClone Domain Mutagenesis kit
(Stratagene) was used to create a library of random
mutants. Mutagenesis primers were designed to subject
the 1–100 30-UTR of AT1R to random mutagenesis.
Sequencing of a random sample of mutagenized
constructs conﬁrmed that the number of nucleotide sub-
stitutions per cDNA ranged from two to four. In order
to search for mutants with altered steady-state mRNA
levels 100 constructs were tested. Five clones showed inter-
esting results in either increasing or decreasing steady-
state luciferase activity.
Real-time PCR
In RNA half-life experiments, cells were immersed in
fresh media containing 1mg/ml ( 0.8mM) actinomycin
D (Tocris) to inhibit transcription and incubated at
378C. At the indicated times, cells were harvested and
total cellular RNA was isolated with Nucleospin RNA
II kit (Macherey-Nagel). RNA was treated with DNase
I (Ambion). The ﬁrst-strand cDNA was synthesized with
Superscript II First Strand Synthesis System for RT-PCR
and oligo(dT)12–18 primer (Invitrogen). Primer sequences
used for PCR ampliﬁcation of luciferase, GAPDH and
b-actin genes have been published earlier (27–29). AT1R
oligos used were gcacaatgcttgtagccaaa (upstream) and
ccctatcggaagggttgaat (downstream). After the ﬁrst
strand cDNA synthesis, serial dilutions were made. The
PCR reactions were performed in LightCycler apparatus
using an LC Fast Start DNA MasterPLUS SYBR Green
Kit (Roche Diagnostics). Thermocycling for each reaction
was performed according to manufacturer’s instructions.
The annealing temperatures were 568C for luciferase,
598C for GAPDH oligos and 608C for AT1R oligos.
The elongation time was calculated by dividing the
size of the amplicon by 25. The ﬂuorescence emitted by
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of the elongation step. The second derivative maximum
method was used to determine the crossing-point values.
The concentrations of unknown samples were then
calculated by setting their crossing points to the standard
curve. For normalization of the expression levels, the
expressions of GAPDH or b-actin were measured. The
relative expression level was obtained by dividing
the values for the gene of interest with the GAPDH or
b-actin value. In addition to the melting curve information
obtained from the LightCycler, the PCR products
were run in 1.5% agarose gel electrophoresis to ensure
that only a right-sized product was ampliﬁed.
RNA probepreparation
cDNA was used as a template for PCR reactions whereby
T7 RNA polymerase promoter sequence was added
to the 50-end of all fragments. RNA transcripts were
synthesized from PCR-generated templates including
the following constructs: 1–100, 1–300, 1–600, 1–847 as
well as from 100–300, 300–600 and 600–887 (Megascript,
Ambion), Table 1. In the in vitro transcription reaction,
we used a ratio of biotin-UTP to standard UTP of 1:3.
RNA probes with or without biotin label were generated
by MEGA shortscript kit according to manufacturers
instructions (Ambion). The protocol has been described
in detail (14).
RNA affinitypurification
RNA aﬃnity puriﬁcation was performed as described
previously (14).
Massspectrometry
Silver-stained protein bands of interest were cut out of
the polyacrylamide gel and ‘in-gel’ digested essentially
as described by Shevchenko et al. (30). Proteins were
reduced with DTT and alkylated with iodoacetamide
before digestion with trypsin (Sequencing Grade
Modiﬁed Trypsin, V5111, Promega). The recovered pep-
tides were, after desalting using Millipore C18 ZipTip
TM,
subjected to matrix-assisted laser desorption/ionization-
time of ﬂight (MALDI-TOF) mass spectrometric analysis.
MALDI-TOF mass spectra for mass ﬁngerprinting and
MALDI-TOF/TOF mass spectra for identiﬁcation by
fragment ion analysis were acquired using an Ultraﬂex
TOF/TOF instrument (Bruker-Daltonik GmbH,
Bremen, Germany). Protein identiﬁcation with the gener-
ated data was performed using Mascot Peptide Mass
Fingerprint and MS/MS Ion Search programs (http://
www.matrixscience.com).
Westernblotting
Western blotting was performed as described previously
(14).
RNA electromobility shiftanalysis (REMSA)
REMSAs were performed with biotinylated probes and
puriﬁed human GAPDH protein (Sigma). In brief,
150ng GAPDH was incubated with  10fmol of 30-UTR
probe in 5mM Hepes (pH 7.9), 7.5mM KCl, 0.5mM
MgCl2, 0.1mM EDTA, 0.5mM DTT, 0.1mg/ml yeast
tRNA, 0.1mg/ml BSA for 30min on ice. In a control
experiment, 100-fold excess of unlabeled competitor
probe was used. Eight percent glycerol was added to
the mixture and the samples were separated by 6%
native PAGE with 0.5  Tris borate-EDTA (TBE) run-
ning buﬀer. REMSA was performed as described pre-
viously (14).
Protein immunoprecipitation (IP)
The assay was performed essentially as described (31).
In this assay, GAPDH was immunoprecipitated from
a3 0 mg cytoplasmic lysate prepared from HEK293
cells with the use of 1mg of polyclonal anti-GAPDH anti-
body or 1mg of monoclonal anti-cyclooxygenase 2 (Cox-2)
antibody. The samples were precleared with protein
G-sepharose beads (Sepharose, Pharmacia Biotech),
GAPDH was immunoprecipitated, protein G-agarose
beads were added to bind with the antibody, and exten-
sively washed with 100mM KCl, 5mM MgCl2,1 0 m M
HEPES, pH 7.0, 0.5% NP-40, 1mM DTT and 100U/ml
RNasin RNAse inhibitor as well as 2mM vanadyl
ribonucleoside complexes solution and protease and
phosphatase inhibitor cocktails. Proteins were digested
with 0.1% SDS and 30mg of proteinase K followed by
RNA extraction with phenol-chloroform-isoamyl alcohol
mixture. RNA was precipitated with 10mg of yeast tRNA
as a carrier. Reverse transcription of the immunopre-
cipitated material was performed with poly-T oligos and
PCR with primers targeting coding region of AT1R
mRNA for 29 cycles (as described in quantitative PCR
section). The products were separated on a 2% agarose
gel producing a band at 163bp.
Table 1. Primers used in the generation of PCR products that served as
templates in in vitro transcription (numbering starts from the beginning
of 30-UTR)
AT1R 30-UTR sense primers (number denotes the
ﬁrst nucleotide of the 30-UTR included in the oligo)
1 TAATACGACTCACTATAGGG catgttc
gaaacctgtc cataaagtaa ttttgtgaaa gaagg
100 TAATACGACTCACTATAGGG gaattga
aggagaaaat gcattatgtgg
300 TAATACGACTCACTATAGGG agcctgc
ttttgtcctg ttatttttta tttccacata aagg
600 TAATACGACTCACTATAGGG gtataat
ggtgttacta aagtcacata taaaagttaa ac
AT1R 30-UTR antisense primers (number denotes the
last nucleotide included in the oligo)
100 ctgaaaagta gctaatgctc atttggtagt gaag
300 cagtaaaatt tctcaaatca acacattcat cgagtttc
600 attgttttgg cagtgtaaac ctataagaca caggttg
847 tataactttg ccagatttta atcaattaac agc
887 tgcaataaaattattttattttaaagtaaatataactttgcc
Control (part of the luciferase coding region)
S TAATACGACTCACTATAGGG
gcgccattctatccgctggaagatggaacc
AS cgcccaacaccggcataaagaattgaagag
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Alternatively, the immunoprecipitated RNA was used for
expression proﬁling. Biotinylated cRNA was prepared,
puriﬁed and fragmented according to Aﬀymetrix protocol
(Expression Analysis Technical Manual, Aﬀymetrix).
Human Genome U133 Plus 2.0 whole human genome
expression array. GeneChips were washed and stained
in the Aﬀymetrix Fluidics Station 400 and scanned using
the Aﬀymetrix GeneChip Scanner 3000. The image data
were analysed with Microarray Suite version 5.0. (MAS5)
using Aﬀymetrix default analysis settings and global
scaling as normalization method.
Computational analysis
Microarray data were analyzed using R (32) and
Bioconductor (33). First, probes were mapped to probe
sets representing Ensembl transcript IDs with custom
probe set deﬁnitions (34) and then normalized with the
RMA quantile normalization method (35). The transcripts
were ordered according to their expression values to
ﬁnd the most strongly enriched putative GAPDH targets.
The 30-UTR sequences were retrieved for the transcripts
when available from the Ensembl database (36). The
training data set from which the motifs were derived was
constructed as follows. First, we used only sequences with
length between 50 and 500bp due to computational
complexity with the longer sequences. Second, if a
sequence was an identical or partial subsequence of
another sequence it was excluded from the analysis since
almost identical sequences can severely bias the motif
ﬁnding process. From these sequences we chose n tran-
scripts having the highest expression value to the training
data set. CMFinder was used to derive the motifs from
the unaligned sequences (37). Sizes used for the training
data set were 10, 20, 30, 50, 100, 150 and 200. The
1–100bp sequence of ATIR was added to the training
data set to guide the motif ﬁnding process. From the
potential motifs those that hit the ATIR sequence with
at least a bit score of 10 were selected for further analysis.
The signiﬁcance of the putative motifs was tested by calcu-
lating the ratio of the number of hits per kilobases
between the training data set and the reference data set.
The reference data set included all the available 30-UTR
sequences of the transcripts on the microarray. The pro-
gram Infernal (http://infernal.janelia.org/) was used to
search hits with at least a bit score of 10 against the
sequence sets. The motifs with highest enrichment ratio
were considered the most interesting.
Ligand-binding assay
AT1R binding was measured using subconﬂuent cells
grown in 24-well plates. The assay was performed as
described previously (38).
In vitro translation
In vitro translation reactions were performed using
ﬂexi rabbit reticulocyte lysate system (Promega) as des-
cribed by manufacturer. Protein synthesized in vitro were
labelled with biotinylated lysine tRNA. Puriﬁed human
GAPDH was purchased from Sigma and 50 and
150ng were added to translation reaction when appro-
priate. The results were evaluated by luciferase assay
as well as by western blotting. In the western blot, the
in vitro translation products were detected using strepta-
vidin-HRP according to manufacturer’s protocols
(Promega).
RESULTS
AT1R3’-UTR decreasesprotein expression
To test the hypothesis that cis-acting elements within the
AT1R 30-UTR have an important role in posttranscrip-
tional regulation, we measured luciferase activities and
mRNA levels in the presence or absence of AT1R
30-UTR. Constructs contained luciferase coding sequence
with or without AT1R 30-UTR sequence and the SV40
late poly(A) signal. The full-length AT1R 30-UTR reduced
luciferase activity by  70–80% when compared with
30-UTR-less construct. Western blotting results were
similar to luciferase activities (data not shown). Quantita-
tive PCR revealed luciferase RNA expression to be
decreased  50% by AT1R 30-UTR. The reverse comple-
ment of the AT1R 30-UTR segment was cloned into the
pGL3-Promoter vector downstream of the luciferase
coding region. This construct reduced luciferase activity
by  10% of promoter control or approximately one-
sixth of the reduction attributable to the sense orientation
of the 30-UTR construct (Figure 1A). A pGL3 vector
was constructed in which luciferase gene was replaced by
AT1R coding region. Similarly to luciferase-AT1R
30-UTR fusion construct, mRNA levels were lower with
full length AT1R construct compared with AT1R coding
region only (Figure 1B). These results indicate that
30-UTR regulates both mRNA levels and protein
expression.
AT1R 30-UTR decreases mRNA half-life and sup-
presses mRNA translation. To understand the mecha-
nisms of AT1R 30-UTR-mediated decrease in protein
expression, mRNA half-life and translation were evalu-
ated. In order to study the eﬀect of 30-UTR on mRNA
stability, transcription was halted by including actinomy-
cin D to the medium. After various incubation periods
the reaction was terminated and luciferase mRNA was
extracted and analyzed by quantitative PCR. This data
shows that 30-UTR increases the rate of mRNA degra-
dation (Figure 1C). To examine if AT1R 30-UTR has
any eﬀect on the translation, in vitro translation was per-
formed in the presence and absence of 30-UTR. Luciferase
activity of the translation products was measured. In
addition, translation products were separated by SDS–
PAGE, electroblotted and biotin-labelled translation
products were detected by streptavidin-HRP. The size
of the band was  60kDa consistent with luciferase
molecular weight. These results show a  60% inhibition
of luciferase translation by AT1R 30-UTR (Figure 1D).
Based on these experiments, AT1R 30-UTR decreases
receptor expression by destabilizing mRNA and by sup-
pressing mRNA translation.
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Next, we sought to identify the AT1R 30-UTR mRNA
interacting proteins that would mediate 30-UTR-
dependent eﬀects. We assayed the existence of such
RNA-binding proteins by employing aﬃnity puriﬁcation.
Probes corresponding to 30-UTR constructs 1–100, 1–300,
1–600 and 1–847 bases were transcribed and poly-A
tail was included as a part of the primer used in the
PCR-reaction. Due to problems in transcribing the
full-length RNA construct, the longest polyadenylated
RNA transcript used in the aﬃnity puriﬁcation did not
include the last 40bp in 30-end of the 30-UTR. Schematic
representations of the probes are described in Figure 2A.
Synthesized mRNAs with poly-A were bound to poly-T
beads, incubated with cytoplasmic lysates followed
by extensive washing. Figure 2B is a silver-stained gel
showing the protein pattern of fractions eluted from
AT1R 30-UTR mRNA. The most abundant band
migrated at  36kDa and this band was present with all
the AT1R 30-UTR probes used. Binding was undetectable
in reactions using fragments of luciferase coding region
as a negative control. Protein was excised from the gel
and digested ‘in gel’ by trypsin. The generated peptides
were extracted and subjected to mass spectrometric ana-
lysis. Database (MSDB) search with the combined
MALDI-TOF peptide mass ﬁngerprint and MALDI-
TOF/TOF peptide fragment ion data identiﬁed (Mascot
score 238.0) the protein as human GAPDH. Human
GAPDH is a basic protein and results in 36 tryptic
peptides. Only eight have a molecular weight between
1000 and 2500 Da. Five of these peptides found in the
mass ﬁngerprinting corresponded to an intensity coverage
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Figure 1. 30-UTR of AT1R is a negative regulator of AT1R expression. (A) The eﬀect of AT1R 30-UTR on luciferase activity (white bars). Three
diﬀerent constructs were studied: luciferase, luciferase with AT1R 30-UTR and luciferase fused with AT1R 30-UTR in reverse orientation. HEK293
cells were transfected with a luciferase and renilla luciferase plasmids. Cells were lysed and assayed for ﬁreﬂy and renilla luciferase activities. To
evaluate mRNA levels, luciferase and GAPDH mRNA levels were measured by quantitative PCR. Corrected luciferase mRNA expression values
were calculated by dividing luciferase mRNA by GAPDH mRNA expression (black bars). Values were normalized to the activity or mRNA levels of
a luciferase reporter lacking the AT1R 30-UTR to account for the eﬀect of 30-UTR.  P<0.05 versus luciferase without 30-UTR. (B) The eﬀect of
30-UTR on AT1R mRNA was evaluated. We compared the mRNA levels of AT1R coding region with or without 3’-UTR. AT1R and GAPDH
mRNA levels were determined by quantitative PCR using AT1R coding region speciﬁc oligos. AT1R expression was corrected by GAPDH
expression. Data were normalized to the activity of AT1R construct lacking the 30-UTR. The results represent the means   SD of an average of
three independent experiments performed in triplicate for each construct.  P<0.05 versus AT1R without 30-UTR. (C) Measurement of the rate of
degradation of luciferase mRNA. HEK293 cells were transiently transfected with luciferase construct with or without the full length AT1R 30-UTR.
Transfected cells were then treated with actinomycin D for 5min, 10min, 15min and 30min. Quantitative PCR was performed with luciferase and
GAPDH speciﬁc oligos and luciferase mRNA expression was normalized by GAPDH. The mRNA measurements for each construct were normalized
to the expression of the construct at time zero. Results are shown as a linear ﬁt. Results represent the means of an average of three independent
experiments performed as a triplicate for each construct. (D). Measurement of the rate of luciferase translation in rabbit reticulocyte lysates. In vitro
translation of chimeric luciferase constructs with and without 30-UTR were compared. From the in vitro translation reaction mixture luciferase
activity was measured (upper panel) and western blot analysis was performed (lower panel). Translated proteins were detected with streptavidin-HRP
detection system.  P<0.05 versus luciferase without 30-UTR.
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CATGTTCGAAACCTGTCCATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCAC CATGTTCGAAACCTGTCCATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCAC
TACCAAATGAGCATTAGCTACTTTTCA TACCAAATGAGCATTAGCTACTTTTCAGAATTGAAGGAGAAAATGCATTATGTGGACTGAACCGACTTTTCTA GAATTGAAGGAGAAAATGCATTATGTGGACTGAACCGACTTTTCTA
AAGCTCTGAACAAAAGCTTTTCTTTCCTTTTGCAACAAGACAAAGCAAAGCCACATTTTGCATTAGACAGATG AAGCTCTGAACAAAAGCTTTTCTTTCCTTTTGCAACAAGACAAAGCAAAGCCACATTTTGCATTAGACAGATG
ACGGCTGCTCGAAGAACAATGTCAGAAACTCGATGAATGTGTTGATTTGAGAAATTTTACTGACAGAATGCAA ACGGCTGCTCGAAGAACAATGTCAGAAACTCGATGAATGTGTTGATTTGAGAAATTTTACTGACAGAATGCAA
TCTCCCTAGCCTGCTTTTGTCCTGTTATTTTTTATTTCCACATAAAGGTATTTAGAATATATTAAATCGTTAG TCTCCCTAGCCTGCTTTTGTCCTGTTATTTTTTATTTCCACATAAAGGTATTTAGAATATATTAAATCGTTAG
AGGAGCAACAGGAGATGAGAGTTCCAGATTGTTCTGTCCAGTTTCCAAAGGGCAGTAAAGTTTTCGTGCCGGT AGGAGCAACAGGAGATGAGAGTTCCAGATTGTTCTGTCCAGTTTCCAAAGGGCAGTAAAGTTTTCGTGCCGGT
TTTCAGCTATTAGCAACTGTGCTACACTTGCACCTGGTACTGCACATTTTGTACAAAGATATGCTAAGCAGTA TTTCAGCTATTAGCAACTGTGCTACACTTGCACCTGGTACTGCACATTTTGTACAAAGATATGCTAAGCAGTA
GTCGTCAAGTTGCAGATCTTTTTGTGAAATTCAACCTGTGTCTTATAGGTTTACACTGCCAAAACAATGCCCG GTCGTCAAGTTGCAGATCTTTTTGTGAAATTCAACCTGTGTCTTATAGGTTTACACTGCCAAAACAATGCCCG
TAAGATGGCTTATTTGTATAATGGTGTTACTAAAGTCACATATAAAAGTTAAACTACTTGTAAAGGTGCTGCA TAAGATGGCTTATTTGTATAATGGTGTTACTAAAGTCACATATAAAAGTTAAACTACTTGTAAAGGTGCTGCA
CTGGTCCCAAGTAGTAGTGTCTTCCTAGTATATTAGTTTGATTTAATATCTGAGAAGTGTATATAGTTTGTGG CTGGTCCCAAGTAGTAGTGTCTTCCTAGTATATTAGTTTGATTTAATATCTGAGAAGTGTATATAGTTTGTGG
TAAAAAGATTATATATCATAAAGTATGCCTTCCTGTTTAAAAAAAGTATATATTCTACACATATATATATATG TAAAAAGATTATATATCATAAAGTATGCCTTCCTGTTTAAAAAAAGTATATATTCTACACATATATATATATG
TATATCTATATCTCTAAACTGCTGTTAATTGATTAAAATCTGGCAAAGTTATATTTACTTTAAAATAAAATAA TATATCTATATCTCTAAACTGCTGTTAATTGATTAAAATCTGGCAAAGTTATATTTACTTTAAAATAAAATAA
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Figure 2. GAPDH interacts with AT1R 30-UTR. (A) A schematic of AT1R mRNA transcript as well as deleted and truncated transcripts used in
aﬃnity puriﬁcation and gel shift assays. (B) Search for RNA-binding proteins that form a complex with AT1R 30-UTR. The details of the puri-
ﬁcation are given under ‘Materials and Methods’ section. Lane 1: Luciferase coding region template was used as a control. Lanes 2–5: In vitro
transcribed truncated fragments of AT1R 3’-UTR were used in the aﬃnity puriﬁcation. The diﬀerentially expressed 36kDa protein was excised,
digested, and the resulting peptides were recognized by mass spectrometry. (C) REMSA. After binding reaction, excess unbound RNA was digested.
In lane 1A biotinylated control probe of luciferase coding region without GAPDH was used. Lane 2 has the same control probe as lane 1 but 150ng
of puriﬁed GAPDH protein was added. Lane 3 had biotinylated 30-UTR 1–100 transcript without GAPDH, lane 4 had 150ng of GAPDH and lane 5
had both 150ng of GAPDH as well as 100-fold excess of unlabelled probe included in the binding mixture. (D) Binding of endogenous GAPDH with
endogenous AT1R mRNA was detected by RT-qPCR assay with AT1R speciﬁc primers of material obtained by IP from cytoplasmic fractions.
(continued)
Nucleic Acids Research,2009, Vol.37, No. 7 2351of 59.3%. The two peptides (1762795 and 1410783Da)
subjected to MALDI-TOF/TOF analysis also individually
identiﬁed the protein as human GAPDH with Mascot
MS/MS Ion Search Program scores 130 and 94.70, respec-
tively. Aﬃnity puriﬁcation results were conﬁrmed by
Western blot using polyclonal GAPDH antibodies (data
not shown). As our longest probe did not have the 30-end
of the 30-UTR bases, calreticulin was not puriﬁed by aﬃ-
nity puriﬁcation. We did observe the binding of AUF-1 to
AT1R 30-UTR consistent with prior publications (data
not shown) (12).
GAPDH bindingto endogenous andrecombinant AT1R
mRNA
We ﬁrst tested whether GAPDH binds directly to AT1R
30-UTR, REMSA was performed with puriﬁed GAPDH
protein. To this end, a transcript spanning 1–100 region
of AT1R 30-UTR was synthesized but no poly-A tail
was added. Control transcript transcribed from luciferase
coding region did not show gel shift with GAPDH.
In contrast, a 1–100 fragment of AT1R 30-UTR mRNA
showed a shift with GAPDH that was competed by
100-fold excess of unlabeled probe. Gel shift with puriﬁed
protein is consistent with a direct interaction (Figure 2C).
REMSA performed with puriﬁed protein has two bands
and it is possible that the upper band is due to GAPDH
dimers or oligomers (41). This experiment also shows
that polyadenylation of the transcript is not required
for GAPDH’s interaction with mRNA. Second, ribonu-
cleoprotein (RNP) IP was performed to study the associ-
ation of GAPDH with endogenous AT1R mRNA. The
relative enrichment of AT1R mRNA in RNP IP reaction
was also tested by RT, followed by conventional PCR
ampliﬁcation and then visualized on agarose gels. RNP
IP assays revealed a strong enrichment of AT1R mRNA
with GAPDH in anti-GAPDH antibody reactions relative
to that of control IP reactions (IgG and cox-2)
(Figure 2D). These results indicate that GAPDH forms
RNP complex with endogenous AT1R mRNA. Third,
we wanted to identify the AT1R 30-UTR mRNA regions
involved in associating with GAPDH. To this end, several
polyadenylated transcripts spanning the diﬀerent mRNA
regions were synthesized. Following in vitro binding
assays with cell lysates, the interaction between the tran-
scripts and the cytosolic extract was assessed by aﬃnity
puriﬁcation followed by western blotting. These observa-
tions supported a binding scheme on the AT1R 30-UTR
whereby GAPDH associated preferentially with the
proximal 100bp of the 30-UTR (Figure 2E). To deﬁne
GAPDH-binding site in more detail, we performed
random mutagenesis of 1–100 region of the full length
AT1R 30-UTR. PCR-based mutagenesis was used to
introduce on average two to four mutations in each
clone. We isolated a clone in which residues 9 and 11
(counting from the beginning of 30-UTR) were deleted
to have a 4-fold increase in luciferase (data not shown).
We hypothesized that this would be due to loss of
GAPDH-binding to the 30-UTR. In an in vitro binding
assay GAPDH binding was reduced consistent with
the idea that increased expression of mutant Del 9/11 is
mediated by loss of GAPDH-mediated translation sup-
pression, Figure 2F. The loss of interaction by deletion
of residues 9 and 11 in the full length AT1R 30-UTR
was conﬁrmed by gel shift, Figure 2G. Interestingly,
REMSA performed with HEK293 cytoplasmic protein
lysate has only one band instead of two seen with the
puriﬁed GAPDH (Figure 2C). Pure GAPDH may have
in the absence of other protein partners’ higher tendency
to form protein dimers. Together, these ﬁndings indicated
that GAPDH speciﬁcally binds the AT1R mRNA, both
endogenous and in vitro transcribed, and that binding
occurs in the 1–100 region of AT1R 30-UTR.
Sequence andstructure of predicted GAPDH-binding motif
A collection of mRNAs that were GAPDH targets was
identiﬁed. GAPDH was immunoprecipitated from
HEK293 and the bound mRNA was exctracted and
reverse transcribed, and the resulting products were
hybridized to Aﬀymetrix arrays. IgG was used as a control
and the amount of mRNA immunoprecipitated under
our conditions was very low. Transcripts corresponding
to 6% of all genes on the array were substantially enriched
in GAPDH IP compared with IgG IP. The RNA
sequences were subjected to computational analysis (as
described in ‘Materials and Methods’ section) to identify
GAPDH motif based on secondary structures. The
sequence alignment motif representation of relative
frequency of nucleotides at each position and the examples
of the secondary structures of this putative GAPDH
motif are shown in Figure 3A and B. This analysis
revealed AU-rich motif. The frequency of GAPDH
motif in the database was 0.08hits/kb which is similar to
that of Hur (39). The secondary structures of representa-
tive mRNA with GAPDH-binding motif as well as del
9/11 construct are presented in Figure 3C. Our results
suggest that GAPDH motif appears to be localized
mostly to 30-UTR, it is possible that in some transcripts
the GAPDH motif is localized within the coding region.
Figure 2. Continued
Changes in the level of AT1R mRNA associated with GAPDH were evaluated by measuring its abundance in the IP mixture. Immunoprecipitation
was performed with preimmuno IgG, with GAPDH-speciﬁc antibody, and with anti-cox-2 antibody. PCR products were visualized after electro-
phoresis in 1% agarose gels stained with ethidium bromide. (E) Mapping of the GAPDH-binding site within AT1R 30-UTR. A western blot of
proteins isolated by RNA aﬃnity puriﬁcation was performed and GAPDH expression was detected by polyclonal anti-GAPDH antibodies. (F)
Random mutagenesis of the 1–100 part of AT1R 30-UTR. Mutated 30-UTRs were generated by PCR-based mutagenesis. One hundred clones were
generated and of those ten were sequenced to determine the rate of mutagenesis. Each mutant had 2 to 4 base insertions, deletions or mutations. We
measured the binding of the endogenous GAPDH to the mutants by aﬃnity puriﬁcation. To reduce variability, the same HEK 293 cytoplasmic cell
lysate was used for all these constructs. After protein binding, RNA treatment was performed. (G) REMSA of AT1R 30-UTR Del 9/11. Lane 1. A
biotinylated probe of 1–100 was used as a positive control for GAPDH REMSA. Cell lysate was from HEK293 cells. Lane 2. A biotinylated probe
of 1–100 was used with 10-fold excess of unlabelled probe included in the binding mixture. Lane 3. A biotinylated transcript containing 1–100 del
9/11 that lacks GAPDH-binding site.
2352 Nucleic Acids Research, 2009, Vol. 37,No. 7It should be noted that some GAPDH mRNAs identiﬁed
on the arrays did not appear to contain the motif
described in this study suggesting other motifs may also
exist that were not identiﬁed in this analysis.
GAPDH silencing increases AT1Rexpression
To assess the functional signiﬁcance of GAPDH-AT1R
30-UTR interactions, GAPDH levels were reduced by
RNA interference. GAPDH down-regulation had very
little eﬀect (non signiﬁcant) on the activity of a luciferase
construct lacking GAPDH-binding site. In the luciferase
construct with GAPDH-binding site, GAPDH silencing
caused a 2.5-fold increase in the luciferase activity when
compared to controls (Figure 4A, upper panel). When
GAPDH does not bind to AT1R 30-UTR (no 30-UTR
and del 9/11 constructs), reduction in GAPDH expression
does not alter luciferase activity. These results suggest that
adenines at position 9 and 11 of 30-UTR are critical
for GAPDH binding and for the functional eﬀect of
GAPDH. This increase in luciferase activity could poten-
tially be mediated by stabilization of mRNA or by a relief
of translational suppression upon GAPDH silencing.
In order to evaluate the molecular mechanism of
GAPDH-mediated eﬀects, we measured the RNA-
response to GAPDH silencing. To control for siRNA
silencing eﬃciency, we measured GAPDH expression in
the samples and observed an 8-fold decrease in GAPDH
mRNA as compared to controls (data not shown). In con-
trast to protein levels, GAPDH silencing modestly
decreased mRNA of luciferase fused with AT1R
30-UTR, as measured by quantitative PCR (Figure 4A,
lower panel). This suggests that the predominant eﬀect
of GAPDH on protein expression is not mediated by an
alteration in mRNA decay but rather it is likely that
GAPDH inhibits translation of AT1R by binding to its
30-UTR.
To test directly the role of translation as a molecular
mechanism of GAPDH-induced decrease in AT1R expres-
sion, we performed in vitro translation. To further exam-
ine the molecular mechanism of GAPDH eﬀects,
luciferase construct with and without AT1R 30-UTR was
in vitro translated. Translation reactions were conducted
in the presence of varying concentrations of puriﬁed
GAPDH. The resulting products were measured for luci-
ferase activity as well as separated on a SDS–PAGE gel
and detected with streptavidin-HRP. In keeping with
GAPDH’s silencing eﬀect on protein expression,
GAPDH inhibited protein synthesis of a luciferase con-
struct with AT1R 30-UTR in a concentration dependent
manner (Figure 4B). There was only a minor change in
luciferase translation in the absence of 30-UTR indicating
Figure 3. Sequence and structure of the predicted GAPDH motif, as identiﬁed among GAPDH-bound transcripts. (A) Probability matrix (graphic
logo) of the GAPDH motif indicating the relative frequency of ﬁnding each residue at each position within the motif, as elucidated from the array-
derived experimental data set. (B) Structural alignment of four examples of GAPDH motif in speciﬁc mRNAs. (C) Secondary structure of four
representative examples of the GAPDH motif in speciﬁc mRNAs. RPL14, ribosomal protein L14; PABP1, poly (A)-binding protein 1; PABP3, poly
(A)-binding protein 3; AT1R, angiotensin II type 1 receptor. Furthermore, del 9/11 of AT1R 30-UTR is shown.
Nucleic Acids Research,2009, Vol.37, No. 7 2353that the GAPDH eﬀect is mediated by AT1R 30-UTR.
Inclusion of BSA as a control protein did not have any
eﬀect on translation (data not shown). These results sup-
port the view that GAPDH functions as a translational
repressor of AT1R.
GAPDH silencing increases the expression ofendogenous
AT1R
To test the importance of GAPDH on the expression of
endogenous AT1R in coronary artery VSMCs, we silenced
GAPDH expression. To control for siRNA silencing eﬃ-
ciency, we measured GAPDH expression in the samples
and observed an 8-fold decrease in GAPDH mRNA as
compared to controls (data not shown). As shown in
Figure 5A (upper panel), the use of siRNA targeting
GAPDH increased AT1R protein expression as measured
by ligand binding and thus GAPDH functional eﬀects are
similar in HEK293 cells and coronary artery VSMCs.
GAPDH protein levels were signiﬁcantly decreased by
72h after transfection of a GAPDH-targeting siRNA.
Similarly to HEK293 cells, siGAPDH modestly decreased
AT1R 30-UTR mRNA in coronary artery VSMCs, as
measured by quantitative PCR analysis (Figure 5A,
lower panel). GAPDH stabilizes AT1R mRNA in a
similar way as it has been described to inﬂuence some
other mRNAs (15). We tested whether increased AT1R
expression would lead to enhanced MAPK phosphoryla-
tion by angiotensin II in coronary artery VSMC. AT1R
stimulation by angiotensin II causes ERK phosphoryla-
tion. GAPDH-silenced cells showed stronger phosphory-
lation of ERK MAPKs in response to angiotensin II,
Figure 5B. These results implicate GAPDH in the regula-
tion of AT1R expression.
GAPDH mediates the effectof H2O2on AT1R
Exposure of coronary artery VSMC to hydrogen peroxide
caused a dose-dependent down-regulation of GAPDH
while it increased AT1R expression (24,25), Figure 6A.
Several lines of evidence support the role of GAPDH
in the H2O2-induced regulation of AT1R. Aﬃnity puriﬁ-
cation assay demonstrates that H2O2-treatment of cell
lysates reduced GAPDH binding to both full-length
AT1R 30-UTR and 1–100 of 30-UTR, Figure 6B. In
Figure 6B we see a smaller reduction by H2O2 in full-
length 30-UTR expression (from  1.5- to 2-fold) whereas
with 1–100 there is a larger reduction. The full length
AT1R 30-UTR may be subject to additional counter-
acting regulatory mechanisms. In contrast to intact cells,
GAPDH protein level did not change in cell lysates
exposed to H2O2. In Figure 6C, REMSA performed
with H2O2-treated lysates showed decreased GAPDH
binding to 30-UTR of AT1R in a H2O2-concentration
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and subsequent experiments are expressed as fold of promoter control without 30-UTR in relative light units of ﬁreﬂy luciferase. Results represent the
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protein loading.  P<0.05 versus siControl-treated cells. Lower panel: Luciferase mRNA was quantiﬁed by quantitative PCR. All the results were
normalized to b-actin expression.  P<0.05 versus siControl transfected cells. (B) GAPDH suppresses AT1R 30-UTR translation. The same tran-
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2354 Nucleic Acids Research, 2009, Vol. 37,No. 7dependent manner. Thus, the reduction in GAPDH bind-
ing to AT1R 30-UTR was not entirely due to reduced
GAPDH expression but also due to decreased GAPDH-
binding aﬃnity.
To determine if GAPDH interaction with 30-UTR was
necessary for the H2O2-induced increase in AT1R expres-
sion, we tested the eﬀect of deleting the GAPDH-binding
site in the reporter gene. HEK293 cells were transfected
with luciferase construct either with or without AT1R
30-UTR. Similarly to endogenous AT1R, H2O2 treatment
decreased luciferase-AT1R 30-UTR activity. Deletion of
GAPDH-binding site in 30-UTR led to an attenuated
response to hydrogen peroxide (Figure 6D). We transi-
ently transfected GAPDH to reverse H2O2-induced
decrease in GAPDH expression and indeed found that
GAPDH overexpression attenuated this response. Taken
together, these results indicate that decreased GAPDH
binding to AT1R 30-UTR in response to H2O2 increased
AT1R expression.
DISCUSSION
We found that GAPDH bound the AT1R mRNA and
aﬀected its translation, that H2O2 treatment decreased
(GAPDH-AT1 mRNA) complexes. GAPDH is an abun-
dant protein that is located mainly but not exclusively
within the cytoplasm of cells. It is essential for
glycolysis, but recent evidence suggests it may have several
other important cellular functions. GAPDH binds RNA
through NAD-binding region, however, not much is
known about the sequence speciﬁcity of GAPDH binding
(17). Our data suggest that GAPDH eﬀects on AT1R
expression are governed by cis-element in AT1R mRNA
and mediated by a direct GAPDH–mRNA interaction.
Gel shift shows that the interaction of GAPDH with
AT1R 30-UTR is direct and requires neither miRNA nor
other proteins. GAPDH binding is speciﬁc based on com-
petition experiment in gel shift as well as deletion and
mutagenesis analysis of the sequence requirements for
GAPDH binding within 30-UTR. Deletion of bases at
9 and 11 leads to a loss of GAPDH binding to AT1R
30-UTR. Although there appears to be much ﬂexibility
in the RNA-binding protein binding sites, single muta-
tions have been shown to decrease protein binding to
mRNA (40). It is likely that an alteration in the secondary
structure of AT1R by two single-base deletions removes
essential structural element of the GAPDH-binding site.
AT1R expression is modulated by the level of GAPDH
binding to AT1R mRNA. In an in vitro assay GAPDH
dose-dependently inhibits AT1R translation. Deletion of
GAPDH-binding site from the 30-UTR increases reporter
gene activity consistent with the loss of GAPDH-mediated
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Figure 5. Role of GAPDH in the regulation of endogenous AT1R. (A) Upper panel: The eﬀect of GAPDH silencing on AT1R expression in early
passage (3–5) coronary artery VSMCs. VSMCs were transfected with 30nM GAPDH siRNA or equal amount of control siRNA. AT1R expression
was quantiﬁed by ligand binding. The western blot below demonstrates the eﬀect of GAPDH siRNA on GAPDH expression. Lower panel: AT1R
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points, proteins extracted and results analyzed by western blotting using anti-phospho-ERK antibody, GAPDH antibodies, and b-tubulin antibody.
Nucleic Acids Research,2009, Vol.37, No. 7 2355translation suppression. Similar eﬀect was achieved by
reducing GAPDH expression. GAPDH silencing reduced
GAPDH binding to AT1R mRNA and increased AT1R
expression. The reversal of the GAPDH-mediated trans-
lation inhibition by deletion of GAPDH-binding site
within 30-UTR, further argues for the exquisite speciﬁcity
of GAPDH’s interaction with a deﬁned 30-UTR sequence
of the AT1R mRNA to cause translation inhibition.
GAPDH silencing and 30-UTR mutation del 9/11 increase
AT1R expression by decreasing GAPDH binding to
30-UTR, therefore providing a strong argument for a
direct link between GAPDH and AT1R expression.
As shown in this report, H2O2 treatment decreased
GAPDH binding to AT1R mRNA, thereby increasing
AT1R expression. Accordingly, loss of GAPDH-binding
site within 30-UTR resulted in a loss of H2O2 response,
while overexpression of GAPDH attenuated H2O2
response. Similarly to GAPDH silencing experiments,
decrease in GAPDH expression by oxidative stress led
to decreased GAPDH binding to AT1R mRNA. This
appears to be due to reduced GAPDH expression and
change in GAPDH structure due to oxidative stress (41).
The oxidative stress responsive element and GAPDH-
binding site are the same as 30-UTR mutant lacking
both GAPDH binding and oxidative stress-response,
providing a further argument for a link between
GAPDH and AT1R regulation. Decrease in GAPDH
binding to AT1R 30-UTR by RNA silencing, deleting
GAPDH-binding site, or by oxidative stress led to
increased AT1R expression providing a strong argument
for the role of GAPDH in the posttranscriptional control
of AT1R. In addition to oxidative stress, GAPDH may
regulate the basal expression of AT1R. Interestingly, there
is a 15-fold diﬀerence in GAPDH mRNA in baseline
expression between highest and lowest expressing tissue
(42). Thus, the level of GAPDH-induced transcript-
speciﬁc translational suppression of AT1R varies from
tissue to tissue. Transcript-speciﬁc translational suppres-
sion has been described for a wide variety of transcripts
including b-adrenergic receptor (43), cox-2 (44) and tumor
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2356 Nucleic Acids Research, 2009, Vol. 37,No. 7necrosis factor a (45), for example. Although there are
several proteins that inhibit translation by binding to the
30-UTR including TIA-1 and Ago1, the molecular mech-
anism of translation inhibition by 30-UTR-binding pro-
teins remains unclear.
Computational analysis of GAPDH-binding mRNAs
led to elucidation of AU-rich motif present in GAPDH
target mRNAs. GAPDH-binding motif found in AT1R
mRNA can also be found in  3% of transcripts suggest-
ing that it has a more general role in cellular mRNA
regulation. Two well-characterized RBPs, HuR and
TIAR, have a large number target mRNAs and it could
be that RBP have fairly broad target speciﬁcity (39,40).
Depending on target mRNA, GAPDH either regulates
mRNA stability or translation (46). It appears to be
common for RBPs to have mRNA-dependent functional
eﬀects. In many instances, the same RNA-binding pro-
tein mediates both RNA destabilization and translational
silencing (47,48). A well-characterized The Embryonic
Lethal Abnormal Vision (ELAV)-like protein HuR
regulates both mRNA stability and translation of the
mRNAs it binds.
In summary, we identiﬁed human AT1R 30-UTR as a
potent negative regulator of mRNA expression through
inhibition of translation and destabilization of mRNA.
Posttranscriptional regulation of AT1R is a complex inter-
play of positive regulators such as p100 (14) and negative
regulators such as GAPDH, calreticulin (6) and AUF1
(12). Translational suppression of AT1R mRNA by con-
verting it to an untranslatable or less translatable form
by interaction with GAPDH reduces the AT1R mRNA
translation. The ability to regulate the expression of
AT1R by altering translation eﬃciency would be a rapid
and eﬃcient way to control receptor expression, especially
in response to oxidative stress in kidneys, blood vessels
and the heart.
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